Meningioma is the most common primary central nervous system tumor, originating from the arachnoid cap cells of the meninges surrounding the brain and spinal cord. Primarily benign and slow-growing, these lesions require precise MRI imaging, grading according to WHO classification, and targeted microsurgical or radiosurgical treatment strategies.
Meningiomas are primary brain tumors that originate from the meninges, the thin protective layers covering the brain and spinal cord, and represent one of the most frequently diagnosed intracranial tumors. Representing approximately 30% of all intracranial tumors, meningiomas are usually benign and slow-growing, but depending on their size and location, they can cause significant neurological deficits. They constitute a major category among primary brain tumors and spinal tumors.
Meningiomas most commonly develop intracranially but can also originate in the spinal canal, where they account for about 25-30% of spinal tumors.
Causes and Risk Factors
The precise meningioma causes remain incompletely understood, but several risk factors have been identified:
- Genetic mutations: Particularly alterations in the NF2 gene are strongly linked to tumor development. Learn more about neurofibromatosis.
- Exposure to ionizing radiation: Prior radiation therapy to the head or spine increases risk.
- Hormonal influences: The higher incidence in women, along with detection of estrogen and progesterone receptors in many tumors, suggests hormonal involvement.
- Age and gender: Most diagnoses occur between ages 40 and 70, with a female predominance.
Pathology and Classification
1. Histopathological Features
Meningiomas derive from arachnoid cap cells and typically consist of spindle-shaped cells arranged in whorls or sheets. Psammoma bodies—calcified, concentric microscopic structures—are commonly observed. The degree of cellular atypia and mitotic activity varies by tumor grade.
2. WHO Classification (2021 Update)
Based on histological and clinical behavior, meningiomas are categorized into three grades:
Grade I: Benign
Well-differentiated, slow-growing, low recurrence risk.
Subtypes: Meningothelial, Fibrous (Fibroblastic), Psammomatous, Angiomatous, Microcystic, Secretory.
Grade II: Atypical
Elevated mitotic activity, brain invasion, increased recurrence risk.
Subtypes: Atypical, Clear Cell, Chordoid.
Grade III: Anaplastic/Malignant
Marked atypia, rapid growth, aggressive, poor prognosis.
Subtypes: Anaplastic, Papillary, Rhabdoid.
Clinical Presentation
1. Intracranial Meningiomas
Symptoms vary by tumor size and location, often developing gradually:
- Persistent or worsening headaches
- Seizures (new onset or poorly controlled)
- Focal neurological deficits such as weakness, sensory loss, or speech impairment
- Visual disturbances if tumors compress the optic nerves or chiasm
- Hearing loss or tinnitus with temporal lobe involvement
- Signs of increased intracranial pressure including nausea, vomiting, and papilledema
- Cognitive or behavioral changes, especially in frontal lobe tumors
2. Spinal Meningiomas
Though less common, spinal meningiomas comprise 25-30% of spinal tumors and primarily affect the thoracic spine:
- Gradual onset of back pain and radicular pain radiating along nerve roots
- Motor weakness, sensory deficits, and gait disturbances
- In advanced cases, myelopathy resulting from spinal cord compression
Diagnostic Approach
Neurological Examination
Comprehensive evaluation of motor, sensory, cranial nerve, and reflex functions is essential.
Magnetic Resonance Imaging (MRI)
The gold standard for both cranial and spinal meningiomas. MRI delineates tumor size, dural attachment (notably the “dural tail sign”), involvement of adjacent structures, and provides excellent soft tissue contrast. Contrast-enhanced T1-weighted sequences typically reveal intense homogeneous enhancement.
Computed Tomography (CT)
Useful for detecting calcifications and bone changes, especially skull hyperostosis or erosion in cranial meningiomas.
Dotatate PET MR
Functional imaging modality detecting somatostatin receptor expression in meningiomas. It is especially useful for identifying residual or recurrent disease after surgery or radiotherapy, thereby guiding targeted medical therapies.
Treatment Modalities
1. Microsurgical Resection
The primary and often curative treatment for meningiomas is surgical removal. The extent of resection is graded by the Simpson scale, which correlates with recurrence risk. Complete resection including affected dura and bone offers the lowest recurrence risk.
2. Radiotherapy
Indicated when complete surgical resection is not feasible or for higher-grade tumors. Stereotactic radiosurgery is preferred for small, well-circumscribed lesions or residual lesions. Fractionated external beam radiotherapy is utilized for larger, invasive, or recurrent tumors.
3. Medical Therapy: Somatostatin Analogs
Many meningiomas express somatostatin receptors, making somatostatin analogs like Octreotide valuable adjuncts, particularly in recurrent, unresectable, or radiotherapy-resistant tumors. Treatment decisions are informed by DOTATATE PET/MR receptor imaging to optimize targeted therapy and disease control.
Prognosis
Overall prognosis depends on tumor grade, location, size, extent of resection, and patient factors. Benign meningiomas have excellent long-term survival, while atypical and anaplastic variants necessitate vigilant management.
Frequently Asked Questions
What is a meningioma?
A meningioma is a primary central nervous system tumor originating from the meninges (the protective layers covering the brain and spinal cord), representing about 30% of all intracranial tumors.
Are meningiomas cancerous or benign?
The majority (about 80-85%) of meningiomas are benign (WHO Grade I). However, WHO Grade II (atypical) and WHO Grade III (anaplastic/malignant) variants can show aggressive growth and higher recurrence rates.
What are the common symptoms of a meningioma?
Symptoms depend on tumor location and may include progressive headaches, seizures, visual or hearing changes, limb weakness, cognitive alterations, or back pain in spinal meningiomas.
How is a meningioma diagnosed?
Diagnosis is established via contrast-enhanced MRI (often demonstrating a characteristic dural tail sign), CT scans for bone changes/calcifications, DOTATATE PET MR for receptor mapping, and histopathological tissue analysis.
What is the primary treatment for meningioma?
Maximal safe microsurgical resection is the primary and often curative treatment option. Stereotactic radiosurgery or radiation therapy is utilized for residual, recurrent, or high-grade tumors.
What role does DOTATATE PET MR play in meningioma care?
DOTATATE PET MR detects somatostatin receptor expression in meningioma cells, helping differentiate tumor tissue from scar tissue and guiding targeted somatostatin analog medical therapies.